Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy

Movement Disorders

Volumn 18, Issue 2, 2003, Pages 186-190

  Holmberg, Björn ^a   Johnels, Bo ^a   Blennow, Kaj ^a   Rosengren, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

amyloid; Cerebrospinal fluid; Multiple system atrophy; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; ISOPROTEIN; AMYLOID BETA PROTEIN (2 42); AMYLOID BETA-PROTEIN (2-42); PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PATHOGENESIS; PATIENT REFERRAL; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SHY DRAGER SYNDROME; VOLUNTEER; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; AMYLOID BETA-PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0037295255     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10321     Document Type: Review

References (31)

1. Daniel SE. The neuropathology and neurochemistry of multiple system atrophy. In: Mathias CJ, Bannister R, editors. Autonomic failure: a textbook of the autonomic nervous system. 4th ed. Oxford: Oxford University Press; 1999. p 321-328.
2. Golbe L, Davis P. Progressive supranuclear palsy. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore: Williams and Wilkins; 1993. p 145-161.
3. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1987;45:1-18.
4. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994; 117:235-243.
5. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple system atrophy compared to Parkinson's disease. Mov Disord 1998;13:70-77.
6. Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of parkinsonian syndromes. Parkinsonism Relat Disord 2001;8:23-31.
7. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2018.
8. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999;23;1090-1093.
9. Tamaoka A, Kondo T, Odaka A, Sahara N, Sawamura N, Ozawa K, Suzuki N, et al. Biochemical evidence for the long-tail form (A beta 1-42/43) of amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's disease. Biochem Biophys Res Commun 1994;205:834-842.
10. Andreasen N, Blennow K. β-amytoid protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. Peptides 2002;23:1205-1214.
11. Van Everbroeck B, Green AJE, Phals P, Martins JJ, Cras P. Decreased levels of amyloid β 1-42 in cerebrospinal fluid of Creutzfeldt-Jakobs disease patients. J Alzheimer Dis 1999;1:419-424.
12. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, et al., Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000;54:1099-1102.
13. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
14. Sjogren M, Minthon L, Davidsson P, Granerus A-K, Clarberg A, Vanderstichele H, Vanmechelen F, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal ageing. J Neural Transm 2000;107: 563-579.
15. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189-192.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinsonism- a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, et al. Clinical Research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
18. Quinn NP. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 1989;Jun(Suppl.):78-89.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
20. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, et al. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-258.
21. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197-204.
22. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol. 1995;26:231-245.
23. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
24. Paik SR, Lee JH, Kim DH, Chang CS, Kim YS. Self-oligomerization of NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal A beta fragment (residues 25-35). FEBS Lett 1998;421:73-76.
25. Kruger R, Muller T, Riess O. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders. J Neural Transm 2000;107:31-40.
26. Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 1999;9:721-732.
27. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, Takahashi H. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (Berl) 1998;96: 445-452.
28. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
29. Goldstein DS, Holmes C, Cannon RO 3rd, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997;336:696-702.
30. Holmberg B, Kallio M, Johnels B, Elam M. Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of parkinsonian syndromes. Mov Disord 2001;16:217-225.
31. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-870.